https://www.selleckchem.com/pr....oducts/hydroxy-cinna
124 (95% CI 0.091-0.156, p less then 2×10-16). Applying 10% and 70% risk thresholds resulted in a bias-corrected clinical reclassification index for cases and controls of 0.15 and 0.12, respectively. A clinical utility analysis of patient medical records estimated that a CBM-guided strategy would have reduced invasive procedures from 62.9% to 50.6% in the intermediate-risk benign population and shortened the median time-to-diagnosis of cancer from 60 to 21 days in intermediate-risk cancers. Conclusion - Integration of clin
Like
Comment
Share
